Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Royalty Pharma Plc(RPRX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RPRX
10/02/2026: RPRX (5-star) is currently NOT-A-BUY. Pass it for now.
Royalty Pharma is a specialized financial company that generates revenue by acquiring royalty interests in marketed and late-stage biopharmaceutical products. Its main strength lies in its diversified, long-dated portfolio of high-demand therapies, which provides predictable and stable cash flows. The primary growth opportunity involves identifying and funding innovative drug development through non-dilutive capital solutions. Risks include exposure to drug patent expirations, potential regulatory pressure on pricing, and competitive acquisition markets. The company is well-suited for income-focused investors who prioritize stable dividends backed by pharmaceutical cash flows, provided they can monitor the long-term commercial performance of the underlying drugs in the portfolio.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While the portfolio grows, it is more of an income-generating asset class than a high-growth tech model. |
| Momentum investor | Weak fit | The stock often trades based on long-term cash flow predictability rather than short-term price momentum. |
| Value investor | Strong fit | The company offers exposure to pharmaceutical cash flows at often attractive valuations relative to its long-term royalty potential. |
| Dividend investor | Strong fit | Royalty Pharma provides a stable and growing dividend backed by diverse, long-dated royalty interests. |
| Low-risk investor | Mixed fit | While cash flows are recurring, the stock is subject to biotech-sector volatility and regulatory risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock is influenced by broader biotech market trends and macroeconomic interest rate expectations. |
| Valuation risk | Medium | The intrinsic value depends on complex projections of drug sales which can be impacted by future competitive launches. |
| Competition risk (Royalty market) | Medium / high | Increased competition from large investment firms may drive up the prices of future royalty acquisitions. |
| Business quality | Strong | The company holds a unique, diversified, and highly cash-generative portfolio of life-science intellectual property. |
| Dividend income | Medium | Dividends are dependent on the continued commercial success of the underlying partnered drugs. |
| Execution risk | Medium | Success relies on the company's ability to accurately price and acquire new royalties in a competitive environment. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Very Smooth
The stock has followed a highly orderly price path with minimal short-term disruption.
Analysis of Past Performance
Type Stock | Historic Profit 55.33% | Avg. Invested days 73 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/02/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 33.30B USD | Price to earnings Ratio 31.32 | 1Y Target Price 65.12 |
Price to earnings Ratio 31.32 | 1Y Target Price 65.12 | ||
Volume (30-day avg) 3.0M shares | Beta 0.43 | 52 Weeks Range 34.56 - 64.38 | Updated Date 10/02/2026 |
52 Weeks Range 34.56 - 64.38 | Updated Date 10/02/2026 | ||
Dividends yield (FY) 1.56% | Basic EPS (TTM) 1.84 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Royalty Receipts | Revenue generated from commercialized drugs like Trelegy, Imbruvica, and Trikafta. | Royalty Pharma collects a percentage of sales from successful drugs, acting like an investment fund for medicines. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 31.32 | Forward PE 29.41 | Enterprise Value 32.91B | Price to Sales(TTM) 13.13 |
Enterprise Value 32.91B | Price to Sales(TTM) 13.13 | ||
Enterprise Value to Revenue 12.98 | Enterprise Value to EBITDA 19.21 | Shares Outstanding 445.28M | Shares Floating 417.57M |
Shares Outstanding 445.28M | Shares Floating 417.57M | ||
Percent Insiders 6.49 | Percent Institutions 87.33 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Royalty Pharma Plc
Exchange NASDAQ | Headquarters New York, NY, United States | ||
IPO Launch date 1993-03-25 | Founder, Chairman of the Board & CEO Mr. Pablo Legorreta | ||
Sector Healthcare | Industry Biotechnology | Full time employees 100 | Website https://www.royaltypharma.com |
Full time employees 100 | Website https://www.royaltypharma.com | ||
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.